BioAtla, Inc.
BCAB$19M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaSAN DIEGO
Drugs in Pipeline
5
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
6wMarket Overview
Stock performance and key metrics
BCAB News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
CAB-AXL-ADC
Undifferentiated Pleomorphic Sarcoma
BA3071
NSCLC
CAB-ROR2-ADC
Non Small Cell Lung Cancer
Ozuriftamab Vedotin
Head and Neck Cancer
PD-1 inhibitor
Non-Small-Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CAB-AXL-ADC | Phase 2 | Undifferentiated Pleomorphic Sarcoma | - | - |
BA3071 | Phase 2 | NSCLC | - | - |
CAB-ROR2-ADC | Phase 2 | Non Small Cell Lung Cancer | - | - |
Ozuriftamab Vedotin | Phase 2 | Head and Neck Cancer | - | - |
PD-1 inhibitor | Phase 2 | Non-Small-Cell Lung Cancer | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply